The Social Value of Immunotherapy in Non-Small Cell Lung Cancer

J Sullivan; A Sexton Ward; B Korytowsky; D Peneva; J Benner; DN Lakdawalla; B Bolinder; RA Figlin; AB Jena

doi:10.1016/j.jval.2016.03.1523

Abstract only| Volume 19, ISSUE 3, PA167, May 01, 2016

The Social Value of Immunotherapy in Non-Small Cell Lung Cancer

Sullivan J
J Sullivan
Affiliations
Precision Health Economics, Los Angeles, CA, USA
Search for articles by this author
Sexton Ward A
A Sexton Ward
Affiliations
Precision Health Economics, Los Angeles, CA, USA
Search for articles by this author
Korytowsky B
B Korytowsky
Affiliations
Bristol-Myers Squibb, Plainsboro, NJ, USA
Search for articles by this author
Peneva D
D Peneva
Affiliations
Precision Health Economics, Los Angeles, CA, USA
Search for articles by this author
Benner J
J Benner
Affiliations
Precision Health Economics, Los Angeles, CA, USA
Search for articles by this author
Lakdawalla DN
DN Lakdawalla
Affiliations
University of Southern California, Los Angeles, CA, USA
Search for articles by this author
Bolinder B
B Bolinder
Affiliations
Bristol-Myers Squibb, Plainsboro, NJ, USA
Search for articles by this author
Figlin RA
RA Figlin
Affiliations
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Search for articles by this author
Jena AB
AB Jena
Affiliations
Harvard Medical School, Boston, MA, USA
Search for articles by this author

Open ArchiveDOI:https://doi.org/10.1016/j.jval.2016.03.1523

Cancer immunotherapies have demonstrated great efficacy in a wide range of patients, with some achieving extended disease control. We investigated the potential increases in social value that could be gained via widespread use of immunotherapy in treating non-small cell lung cancer (NSCLC).